A Depot Formulation of Sunitinib Malate (GB-102) in Subjects With Neovascular (Wet) Age-related Macular Degeneration

Completed · Phase 1

Conditions studied: Neovascular Age-Related Macular Degeneration

In brief

The purpose of this study is to evaluate the safety and efficacy of single and repeated intravitreal injections of GB-102 in subjects with neovascular (wet) age-related macular degeneration.

Key facts

Study ID

NCT03249740

Run by

Graybug Vision

People needed

32

Starts

2017-08-29

Expected to finish

2019-01-16

Last updated by the study team

2019-12-20

Who can join

Age: 50 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Retinal Consultants of Arizona — Gilbert, Arizona, United States
• Retina-Vitreous Associates Medical Group — Beverly Hills, California, United States
• Midwest Eye Institute — Indianapolis, Indiana, United States
• Ophthalmic Consultants of Long Island — Lynbrook, New York, United States
• Retina Research Institute of Texas — Abilene, Texas, United States
• Texas Retina Associates — Arlington, Texas, United States
• Retina Research Center, PLLC — Austin, Texas, United States
• Medical Center Ophthalmology Associates — San Antonio, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.